文献速递泌尿生殖与妇科肿瘤放疗

在高危局限性或区域非转移性前列腺癌中,恩杂鲁胺联合亮丙瑞林与根治性放疗可耐受且有效:一项2期试验结果

Addition of Enzalutamide to Leuprolide and Definitive Radiation Therapy Is Tolerable and Effective in High-Risk Localized or Regional Nonmetastatic Prostate Cancer: Results From a Phase 2 Trial.
PubMed 文献 · Adv Radiat Oncol · 2022-03-12

这项2期试验在高危局限性或区域非转移性前列腺癌患者中评估恩杂鲁胺联合标准雄激素剥夺治疗与放疗的安全性、耐受性和疗效。16例入组,11例可评估,中位随访35.5个月。所有患者达到PSA完全缓解,1例出现4级不良事件(癫痫),无5级不良事件。作者认为该方案可耐受且有效,需进一步随机对照试验研究。

要点

  • 11例可评估患者中,1例(9%)出现4级不良事件(癫痫),无5级不良事件。
  • 4例(36.4%)出现3级不良事件,如勃起功能障碍和潮热。
  • 所有患者达到PSA完全缓解,中位至PSA完全缓解时间4.2个月。

核心结论

  • 恩杂鲁胺联合标准雄激素剥夺治疗与放疗可耐受且有效,作者认为需在随机对照试验中进一步研究。

研究设计与样本

  • 2期试验,入组标准为至少满足以下2项:cT3a/b期、PSA≥20 ng/mL、Gleason分级8至10、活检核心受累≥33%、或CT或MRI显示盆腔淋巴结受累;排除转移性疾病患者。

主要发现

  • 16例患者入组,2例不符合条件,3例在开始治疗前退出。
  • 中位入组年龄69.0岁(四分位距11.5),中位治疗时长24.0个月(四分位距11.9),中位随访时间35.5个月(四分位距11.2)。
  • 11例中9例(81.8%)完成36个月随访;11例中1例(9%)出现4级不良事件(癫痫),无5级不良事件报告。
  • 11例中4例(36.4%)出现3级不良事件,如勃起功能障碍和潮热。
  • 所有患者达到PSA完全缓解,中位至PSA完全缓解时间4.2个月(四分位距1.4);24个月随访时11例中0例(0%)生化复发,36个月时9例中1例(11.1%)生化复发,该患者因不良事件未完成全部24个月恩杂鲁胺和亮丙瑞林治疗。

关键数值与推荐

  • PSA完全缓解定义为PSA≤0.3。
  • 生化复发定义为PSA最低点+2 ng/mL。

临床怎么用

  • 作者认为,恩杂鲁胺联合标准雄激素剥夺治疗与放疗可耐受且有效,需在随机对照试验中进一步研究。

局限性

  • 作者结论指出需在随机对照试验中进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Enzalutamide is an antiandrogen used to treat both metastatic and nonmetastatic prostate cancer. Here we present results from a phase 2 trial designed to determine the safety, tolerability, and efficacy of adding enzalutamide to standard androgen deprivation therapy with radiation therapy in high-risk localized or regional, nonmetastatic patients with prostate cancer. METHODS AND MATERIALS: Enrollment criteria included at least 2 of the following: stage cT3a/b, prostate specific antigen (PSA) ≥20 ng/mL, Gleason grade 8 to 10, ≥33% core involvement on biopsy, or pelvic lymph node involvement on computed tomography or magnetic resonance imaging. Patients with metastatic disease were excluded. All patients received 24 months of leuprolide and enzalutamide, and 5 weeks of intensity modulated radiation therapy followed by a brachytherapy boost. Adverse events (AE), PSA, testosterone, and basic laboratory tests were then followed for up to 36 months. Primary outcomes were safety and tolerability and PSA complete response rate (PSA-CR, defined as PSA ≤0.3). Secondary outcomes included time to biochemical recurrence (BCR; nadir + 2 ng/mL). RESULTS: Sixteen patients were enrolled; 2 were ineligible and 3 withdrew before starting treatment. Median age at enrollment was 69.0 years (interquartile range [IQR] 11.5). Median treatment duration was 24.0 months (IQR 11.9). Median follow-up time was 35.5 months (IQR 11.2), and 9 of 11 (81.8%) patients completed the 36 months of follow-up. One of 11 (9%) patients had grade 4 AE (seizure), and no grade 5 AE were reported. Four of 11 (36.4%) patients had grade 3 AE, such as erectile dysfunction and hot flashes. All patients achieved PSA-CR, and median time to PSA-CR was 4.2 months (IQR 1.4). At 24 months follow-up, 0 of 11 (0%) patients had a biochemical recurrence. At 36 months, 1 of 9 (11.1%) patient had a biochemical recurrence. Of note, this patient did not complete the full 24 months of enzalutamide and leuprolide due to AEs. CONCLUSIONS: Enzalutamide in combination with standard androgen deprivation therapy and radiation therapy was well-tolerated and effective warranting further study in a randomized controlled trial.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Shee K, de la Calle CM, Chang AJ, et al. Addition of Enzalutamide to Leuprolide and Definitive Radiation Therapy Is Tolerable and Effective in High-Risk Localized or Regional Nonmetastatic Prostate Cancer: Results From a Phase 2 Trial. Adv Radiat Oncol. 2022. PMID: 35847550. doi:10.1016/j.adro.2022.100941

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。